Welcome to our dedicated page for THERALASE TECHS news (Ticker: TLTFF), a resource for investors and traders seeking the latest updates and insights on THERALASE TECHS stock.
Theralase Technologies Inc. (TLTFF) is a clinical stage pharmaceutical company dedicated to developing light and/or radiation activated small molecules for effectively destroying cancers, bacteria, and viruses. Their lead compound, RuvidarTM, has shown promise in inactivating various viruses and increasing efficacy in cancer cell destruction. Recent research has demonstrated RuvidarTM's ability to reverse the charge of BCG, creating a compound, RuBCG, with enhanced cancer cell kill rates. Additionally, Rutherrin® has proven effective in increasing chemotherapy efficacy and reducing multidrug resistance in cancer cells. Theralase is committed to advancing innovative therapies to combat challenging diseases and improve patient outcomes.
Rhea-AI Summary
Theralase Technologies Inc. (TLT) released its 3Q2023 unaudited condensed interim consolidated Financial Statements, reporting a 13% decrease in total revenue. The company experienced a 32% decrease in net research and development expenses for the Drug Division, but a 36% increase in administrative expenses. Theralase also closed a non-brokered private placement, raising over $1.1 million in gross proceeds. The company is working on a Break Through Designation submission to the FDA and provided preliminary clinical data for Study II, demonstrating promising results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
-
Rhea-AI Summary
Theralase Technologies Inc. (TLT) successfully closed a non-brokered private placement offering, raising approximately $CAN 1,170,000 to further the Phase II Non-Muscle Invasive Bladder Cancer clinical study and for working capital needs. The Corporation issued 5,318,183 Units at $0.22 per Unit, each consisting of one Common Share and one Warrant. Insider subscriptions accounted for $101,482 of the gross proceeds, constituting a related party transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
-
Rhea-AI Summary
Theralase® Technologies Inc. (TLT) has initiated a non-brokered private placement of units to raise up to $CAN 1.5 M. Each unit is priced at $CAN 0.22 and includes one common share and one common share purchase warrant. The company plans to use the proceeds for the Phase II Non-Muscle Invasive Bladder Cancer clinical study and working capital needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
Rhea-AI Summary
Theralase Technologies Inc. announces an agreement with Research Capital Corporation for a brokered offering of units at a price of C$0.22 per unit. The offering will raise a minimum of C$3,500,000 and a maximum of C$5,300,000. The company plans to use the proceeds for a clinical study and working capital needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.05%
Tags
-
Rhea-AI Summary
Theralase Technologies has been granted a Clinical Trial Application Amendment by Health Canada for the optimization of the Phase II Non-Muscle Invasive Bladder Cancer clinical study. The optimization includes post-study monitoring of response, optional maintenance treatments, and central pathology laboratory review.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
-
Rhea-AI Summary
Theralase Technologies files US patent for combining immunotherapy drugs with its PDC technology for increased cancer destruction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
-
Rhea-AI Summary
Theralase completes preclinical toxicology analysis of Rutherrin for GBM, demonstrating safe administration and effectiveness in destroying tumor cells
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
-
Rhea-AI Summary
Theralase® Technologies Inc. grants 360,000 stock options to directors and employees at $CAN 0.25 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
Rhea-AI Summary
Theralase Technologies Inc. closes a non-brokered private placement offering of units, raising approximately $460,000. The proceeds will be used for the advancement of a clinical study and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of THERALASE TECHS (TLTFF)?
The current stock price of THERALASE TECHS (TLTFF) is $0.178 as of December 24, 2024.
What is the market cap of THERALASE TECHS (TLTFF)?
The market cap of THERALASE TECHS (TLTFF) is approximately 47.1M.
What is Theralase Technologies Inc. focused on?
Theralase is dedicated to developing light and/or radiation activated small molecules for effectively destroying various cancers, bacteria, and viruses.
What is RuvidarTM and its significance?
RuvidarTM is Theralase's lead compound, proven effective in inactivating viruses and increasing cancer cell destruction efficacy.
How does RuvidarTM impact BCG in cancer treatment?
RuvidarTM reverses the charge of BCG, creating RuBCG, which enhances cancer cell kill rates in bladder cancer therapy.
What is the role of Rutherrin® in chemotherapy?
Rutherrin® effectively increases chemotherapy efficacy and reduces multidrug resistance in cancer cells, offering potential in improving cancer treatment.
What is Theralase's commitment to innovation in healthcare?
Theralase is dedicated to advancing innovative therapies to combat challenging diseases, enhance treatment outcomes, and improve patient quality of life.
THERALASE TECHS INC